Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis

Affiliation auteurs!!!! Error affiliation !!!!
TitreElvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis
Type de publicationJournal Article
Year of Publication2020
AuteursGantner P, Hessamfar M, Souala MFaouzi, Valin N, Simon A, Ajana F, Bouvet E, Rouveix E, Cotte L, Bani-Sadr F, Hustache-Mathieu L, Lebrette M-G, Truchetet F, Galempoix J-M, Piroth L, Pellissier G, Muret P, Rey D, Grp ECFTAFPE
JournalCLINICAL INFECTIOUS DISEASES
Volume70
Pagination943-946
Date PublishedMAR 1
Type of ArticleArticle
ISSN1058-4838
Mots-clésAdherence, Adverse events, completion, HIV, postexposure prophylaxis
Résumé

We evaluated an elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis.
DOI10.1093/cid/ciz577